CDMO Adragos Pharma has inaugurated its new ampoule filling line for sterile injectables at its Livron-sur-Drôme site in France.
This was made possible by a €13m investment by the company, which set out to boost the facility's output by 30% — increasing the company's manufacturing capacity up to 160 million ampoules annually.
The newly installed line, which is the fourth at this facility, offers flexible fill volumes, which range from 1–20mL, allowing Adragos to accomodate a variety of formulations.
It will also allow the CDMO to conduct aseptic fill/finish in accordance with Annex 1 of EU GMP regulations.
As well as the new line at the Livron-sur-Drôme site, Adragos Pharma has added a cleanroom at its Livron facility to enhance its production capabilities further.
Adragos has chosen to expand its Livron-sur-Drôme facility in a time when countries are actively preparing for future pandemics, with requirements in the injectables market continuing to rise.
Gaël Le Saux, Site Head of Livron, highlighted the team’s outstanding execution: "Despite the complexities, the team successfully integrated the new production line without disrupting ongoing operations."
Adragos COO, Marco Gorgas, added: “The new line not only addresses regulatory and capacity demands but also supports our commitment to advancing patient care by meeting the evolving needs of our clients.”
On November 7th, a special event was held to launch the new line, attended by company executives, the mayor of Livron-sur-Drôme, local journalists, and employees, marking a significant milestone in Adragos Pharma’s journey toward sustainable growth.